Schiffman R - Search Results

1

Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients.

Solomon KD, Donnenfeld ED, Raizman M, Sandoval HP, Stern K, VanDenburgh A, Cheetham JK, Schiffman R; Ketorolac Reformulation Study Groups 1 and 2. Solomon KD, et al. Among authors: schiffman r. J Cataract Refract Surg. 2004 Aug;30(8):1653-60. doi: 10.1016/j.jcrs.2004.05.019. J Cataract Refract Surg. 2004. PMID: 15313287 Clinical Trial.

2

Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.

Donnenfeld ED, Nichamin LD, Hardten DR, Raizman MB, Trattler W, Rajpal RK, Alpern LM, Felix C, Bradford RR, Villanueva L, Hollander DA, Schiffman RM. Donnenfeld ED, et al. Among authors: schiffman rm. Am J Ophthalmol. 2011 Mar;151(3):420-6.e1. doi: 10.1016/j.ajo.2010.09.003. Epub 2010 Dec 9. Am J Ophthalmol. 2011. PMID: 21145532 Clinical Trial.

3

Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.

Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R; Combigan Study Group. Craven ER, et al. Among authors: schiffman r. J Ocul Pharmacol Ther. 2005 Aug;21(4):337-48. doi: 10.1089/jop.2005.21.337. J Ocul Pharmacol Ther. 2005. PMID: 16117698 Clinical Trial.

4

Methicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgery.

Olson R, Donnenfeld E, Bucci FA Jr, Price FW Jr, Raizman M, Solomon K, Devgan U, Trattler W, Dell S, Wallace RB, Callegan M, Brown H, McDonnell PJ, Conway T, Schiffman RM, Hollander DA. Olson R, et al. Among authors: schiffman rm. Clin Ophthalmol. 2010 Dec 10;4:1505-14. doi: 10.2147/OPTH.S14333. Clin Ophthalmol. 2010. PMID: 21191448 Free PMC article.

5

A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.

Yee RW, Tepedino M, Bernstein P, Jensen H, Schiffman R, Whitcup SM; Gatifloxacin BID/QID Study Group. Yee RW, et al. Among authors: schiffman r. Curr Med Res Opin. 2005 Mar;21(3):425-31. doi: 10.1185/030079905X30699. Curr Med Res Opin. 2005. PMID: 15811211 Clinical Trial.

6

Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.

Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Abelson MB, et al. Among authors: schiffman rm. Clin Ther. 2004 Jan;26(1):35-47. doi: 10.1016/s0149-2918(04)90004-5. Clin Ther. 2004. PMID: 14996516 Clinical Trial.

7

Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.

Whitcup SM, Bradford R, Lue J, Schiffman RM, Abelson MB. Whitcup SM, et al. Among authors: schiffman rm. Clin Ther. 2004 Jan;26(1):29-34. doi: 10.1016/s0149-2918(04)90003-3. Clin Ther. 2004. PMID: 14996515 Clinical Trial.

8

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.

Goldberg I, Gil Pina R, Lanzagorta-Aresti A, Schiffman RM, Liu C, Bejanian M. Goldberg I, et al. Among authors: schiffman rm. Br J Ophthalmol. 2014 Jul;98(7):926-31. doi: 10.1136/bjophthalmol-2013-304064. Epub 2014 Mar 25. Br J Ophthalmol. 2014. PMID: 24667994 Free PMC article. Clinical Trial.

9

Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.

Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Katz LJ, et al. Am J Ophthalmol. 2010 Apr;149(4):661-671.e1. doi: 10.1016/j.ajo.2009.12.003. Am J Ophthalmol. 2010. PMID: 20346780 Clinical Trial.

10

Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.

Waterbury LD, Galindo D, Villanueva L, Nguyen C, Patel M, Borbridge L, Attar M, Schiffman RM, Hollander DA. Waterbury LD, et al. J Ocul Pharmacol Ther. 2011 Apr;27(2):173-8. doi: 10.1089/jop.2010.0135. Epub 2011 Feb 25. J Ocul Pharmacol Ther. 2011. PMID: 21351868 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

136 results

Search Page